Vagulienė, N. 2020. THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%. Pulmonology and allergology. 4, 2 (Sep. 2020), 164-167. DOI:https://doi.org/10.37499/PIA.119.